Approaches for assessing decision-making capacity in older adults

Usher, Ruth; Stapleton, Thomas

doi:10.11124/jbisrir-d-19-00068

Cited by 9 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…LS-DMC assessments are increasing in hospital settings as the population ages and more people suffer from cognitive decline, which can impact on their ability to live independently and make lifestyle decisions (Usher & Stapleton, 2019). In busy settings, the initial clinical interviews that explore patients' need for living-supports often also include cognitive screens to investigate some of the abilities that underpin DMC (Pachet et al, 2010).…”

Section: Discussionmentioning

confidence: 99%

Use of the QuickSort with older adults whose lifestyle decision-making capacity is being questioned

Foran

Mathias

Bowden

2022

J Int Neuropsychol Soc

View full text Add to dashboard Cite

Objectives:Cognitive impairment affects older adults’ capacity to live independently and make lifestyle decisions (lifestyle decision-making capacity; LS-DMC). Cognitive screens and clinical interviews are often used to assess people’s need for living-supports prior to conducting comprehensive LS-DMC assessments in busy clinical settings. This study investigated whether the QuickSort – a brief new cognitive screen – provides efficient and accurate information regarding patients’ LS-DMC when initially interviewed.Methods:This is an observational and diagnostic accuracy study of older inpatients (≥60 years) consecutively referred for neuropsychological assessment of LS-DMC (n = 124). The resources required by inpatients with questionable LS-DMC were quantified (length of hospital stay, living-supports). QuickSort scores, patient background information, and two common cognitive screens were used to differentiate between older inpatients (n = 124) who lacked (64%)/did not-lack (36%) LS-DMC.Results:Hospitalizations averaged 49 days, with 62% of inpatients being readmitted within one year. The QuickSort differentiated between those lacking/not-lacking LS-DMC better than two common cognitive screens and patient information. The likelihood that inpatients lacked LS-DMC increased by a factor of 65.26 for QuickSort scores <2 and reduced by a factor of 0.32 for scores ≥13. Modeling revealed that the post-test likelihood of lacking LS-DMC increased to 99% (scores <2) and reduced to 30% (scores ≥ 13) in settings where many inpatients lack LS-DMC.Conclusions:Older adult inpatients with questionable LS-DMC have a high risk of extended hospitalization and readmission. The QuickSort provides time-efficient and sensitive information regarding patients’ LS-DMC, making it a viable alternative to longer cognitive screens that are used at the initial interview stage.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of the QuickSort with older adults whose lifestyle decision-making capacity is being questioned

Foran

Mathias

Bowden

2022

J Int Neuropsychol Soc

View full text Add to dashboard Cite

show abstract

“…36 • No specific diagnostic criteria for PD (or Parkinsonism) will be considered if the studies describe their population as presenting the condition, as previously reported. 37 The analysis will not be limited to any clinical setting. All types of quantitative, qualitative, or mixed-method studies will be considered.…”

Section: Inclusion Criteriamentioning

confidence: 99%

Therapeutic potential of dehydroepiandrosterone for Parkinson's disease: scoping review protocol

et al. 2022

View full text Add to dashboard Cite

Background: Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of nigrostriatal dopaminergic neurons. Its treatment is symptomatic and shows limited efficacy. Dehydroepiandrosterone (DHEA) is a hormone produced in the brain. Several studies have reported beneficial effects of the steroid in experimental models of PD and various human diseases, but its potential for PD is inconclusive. Therefore, it is necessary to evaluate current evidence to determine the therapeutic potential of DHEA administration for PD since it could be an effective and low-cost treatment. Objectives: We aim to evaluate the therapeutic potential of dehydroepiandrosterone administration in patients with PD. Inclusion criteria: Studies describing patients with PD receiving DHEA, and reporting an outcome --on disease course, severity, or adverse effects-- compared to either placebo, an inactive treatment or standard treatment. PD experimental models reporting an effect of DHEA treatment on measures of neuroprotection (cell death, motor activity, oxidative stress). Exclusion criteria: Studies written in languages different than Spanish or English that could not be appropriately translated, or whose full-text files could not be retrieved. Information sources: Web of Science, PubMed, Scopus, EBSCOhost, Cochrane Library, Google Scholar, and author's collections. Data charting: Data will be extracted by one researcher and verified by another using a pilot-tested predefined format. Non-systematic review articles (narrative, scoping or similar) will only be considered for narrative synthesis. This protocol complies with PRISMA 2020 statement and its main related extensions (PRISMA-A, PRISMA-P, PRISMA-Scr). It also complies with the Joanna Briggs Institute’s Manual for Evidence Synthesis.

show abstract

“…• No specific diagnostic criteria for HE will be considered if the studies describe their population as presenting this specific condition, as previously reported. 28 • The analysis will not be limited to any clinical setting or article type. All quantitative, qualitative, or mixed-method studies will be considered.…”

Section: Objectivesmentioning

confidence: 99%

Role of manganese in the pathophysiology of hepatic encephalopathy: scoping review protocol

Pérez-Neri¹,

Sandoval²,

Malvaso³

et al. 2022

Arch Neurocien

View full text Add to dashboard Cite

Introduction: Hepatic encephalopathy (HE) is a neuropsychiatric complication of liver disease and/or portosystemic blood shunting, characterized by alterations of alertness, personality, cognition, and motor functions. Its severity is defined from mild symptoms to coma according to four grades. This disease may affect several brain regions including the cingulate gyrus, the insular cortex, and the globus pallidus. The pathophysiology of HE is thought to be multifactorial and involves manganese accumulation in the brain, damaging effect of ammonia on glial cells, etc. Previous studies describe the pathophysiology of HE or the effect of manganese in the central nervous system but there is no review addressing both topics from an integrative perspective and using a systematic methodology. This scoping review aims to evaluate the role of manganese in HE. Methods: Published studies (all publication types) will be retrieved from Web of Science, MEDLINE, Scopus, EBSCOhost, Ovid, and Google Scholar. Inclusion criteria are: studies reporting manganese levels in any biological sample or tissue of patients with HE, any experimental model reporting the effect of manganese administration on measures of neuroprotection in models of liver damage, or showing an effect on manganese levels in the liver and/or the brain. Exclusion criteria are: studies reporting subjects exposed occupationally or environmentally to manganese, or written in languages different than Spanish or English that could not be appropriately translated, or whose full-text files could not be retrieved. Either clinical or preclinical studies will be analyzed separately but might be discussed together. Data summaries will be presented in graphs, figures, and tables. A narrative synthesis will be presented. This protocol complies with PRISMA-P.

show abstract

Approaches for assessing decision-making capacity in older adults

Cited by 9 publications

References 18 publications

Use of the QuickSort with older adults whose lifestyle decision-making capacity is being questioned

Use of the QuickSort with older adults whose lifestyle decision-making capacity is being questioned

Therapeutic potential of dehydroepiandrosterone for Parkinson's disease: scoping review protocol

Role of manganese in the pathophysiology of hepatic encephalopathy: scoping review protocol

Contact Info

Product

Resources

About